Clinical Trial Update: A Study of HS-10516 in Patients With VHL Syndrome Associated Tumors [Phase 1]

View source ↗

Summary

Phase 1 trial update for HS-10516 in Von Hippel-Lindau-associated tumors, currently recruiting for VHL-deficient clear cell renal cell carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Renal Cell Carcinoma
• Von Hippel-lindau Disease

Drugs mentioned

• HS-10516

Snippet

Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd. | Conditions: Von Hippel Lindau-Deficient Clear Cell Renal Cell Carcinoma | Phase 1 | Status: RECRUITING